Circular Genomics was founded on a breakthrough discovery: the direct link between disease and a new class of brain-derived circular RNA biomarkers. This seminal finding isn't just our origin story; it's the cornerstone of our mission to revolutionize the future of neurological and psychiatric treatment with cutting-edge biomarkers for personalized care.

​

Moving beyond today's diagnostic barriers, we harness the power of brain-derived circular RNA biomarkers, providing clinicians with a real-time view of brain disease via simple blood tests. This means more accurate detection of the disease pathology, leading to potentially faster and more informed treatment selection decisions for several neurological and psychiatric conditions. Our innovation drives a movement toward a future where brain disorders are measurable, manageable, and treatable—empowering patients and families to lead fuller lives, which is the core of our vision.​

Our team is passionate and already making a difference for patients and providers. As shown in clinical studies, MindLight, our first commercially available circular RNA biomarker diagnostic, predicts SSRI response in patients suffering from major depressive disorder (MDD) with a diagnostic accuracy of close to 80%. We are actively developing further tests for Alzheimer's disease, among other brain health conditions, and collaborating with leading institutions (such as Washington University in St. Louis) to ensure our solutions are at the forefront of science.​

Circular Genomics is not just developing tests; we are aiming to create a new standard of care. We bring clarity and hope to patients, empowering them and their families. This is the future of brain health.

Paul Sargeant, PhD

President and Chief Executive Officer